Rocket Lab Hits $200 Million

Rocket Lab reported Q1 2026 revenue of $200.3 million, up 63.5% year over year and above the $190 million consensus, while GAAP gross margin hit a record 38.2% and backlog rose to a record $2.2 billion. The company also signed 31 new Electron and HASTE contracts, secured five dedicated Neutron launch agreements, and announced a $30 million HASTE deal with Anduril fully funded by Anduril. Q2 revenue guidance was set at $233 million at the midpoint, with gross margin guidance of 33-35% and an adjusted EBITDA loss of $23 million.

Analysis

The market is starting to price Rocket Lab less like a launch aspirant and more like a defense-enabled manufacturing compounder. The important second-order read-through is that backlog quality is improving: more funded, near-cycle revenue from government and defense customers reduces the historical dependence on “future Neutron optionality” and makes the business easier to underwrite on a 12-18 month basis. That should support a higher multiple not just on growth, but on mix shift toward higher-confidence, higher-margin programs.

The margin progression is the key variable for the next two quarters. If gross margin can hold in the low- to mid-30s while revenue steps up again, EBITDA losses should compress faster than consensus expects, which can force a re-rating before Neutron actually flies. The risk is that the current enthusiasm front-runs execution: large launch backlogs are good headlines, but they also raise the probability of schedule slippage, cost overruns, and working-capital drag as Rocket Lab scales through multiple concurrent programs and acquisitions.

M&A is the subtle wildcard. Mynaric and Motiv increase the strategic narrative around vertical integration, but they also raise integration risk precisely when the company needs clean execution to prove that its addressable market is widening rather than just getting more complex. Competitively, this is most painful for smaller pure-play aerospace subsystems vendors and launch-adjacent contractors that lack Rocket Lab’s balance-sheet flexibility; the company can bundle capabilities, undercut point-solution providers, and win share in defense procurement where speed-to-field matters more than lowest bid.

The contrarian view is that the stock may be discounting too much of the Neutron option value too early. If management’s guidance proves achievable without Neutron contribution, the upside is durable; if not, the market may de-rate the name hard on any launch-delay headline because expectations have moved from ‘story stock’ to ‘execution stock.’ In that sense, the next 3-6 months are more about credibility than revenue, and credibility is much harder to rebuild once the multiple expands.

Key Decisions for Investors

• Go long RKLB on any post-open fade into the first 2-3 sessions after the earnings gap, targeting a 3-6 month hold. Risk/reward improves if the stock retraces part of the pre-market move while backlog and margin inflection remain intact.
• Buy RKLB Jan-2027 call spreads to express the view that the market will re-rate the company on execution before Neutron monetization fully arrives. Prefer defined-risk upside because launch/program timing can be noisy.
• Pair trade: long RKLB / short a basket of small-cap aerospace subcontractors or point-solution space names with weaker balance sheets. The thesis is that Rocket Lab can consolidate share via vertical integration and defense credibility over the next 12 months.
• Avoid chasing the open if implied volatility is elevated; instead, use a two-step entry: partial long on initial consolidation, add only after management commentary confirms gross margin durability and no integration hiccups. Near-term downside risk is a ‘good quarter, bad guide’ reaction if cost ramps accelerate.
• For conservative exposure, sell put spreads 2-4 months out at strikes below the recent earnings gap. This monetizes volatility while positioning for a pullback tied to schedule-risk headlines rather than fundamental deterioration.